PSA
43
6
ABT
54
4
VFC
56
6
ITW
45
2
PWR
63
3
SLB
41
2
HPQ
55
3
EFX
43
3
AMAT
33
3
MPC
28
3
ROP
44
6
BLK
47
3
LMT
29
-5
COP
36
2
MSI
52
3
EQT
47
13
AEE
51
3
EXPD
29
2
EBAY
42
2
FCX
44
4
PSA
43
6
ABT
54
4
VFC
56
6
ITW
45
2
PWR
63
3
SLB
41
2
HPQ
55
3
EFX
43
3
AMAT
33
3
MPC
28
3
ROP
44
6
BLK
47
3
LMT
29
-5
COP
36
2
MSI
52
3
EQT
47
13
AEE
51
3
EXPD
29
2
EBAY
42
2
FCX
44
4
Financhill
Back

Emergent BioSolutions 10K Form

Sell
27

EBS
Emergent BioSolutions

Last Price:
$8.14
Seasonality Move:
1.23%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-02 10Q EBS/Emergent BioSolutions Quarterly
2023-12-11 10Q EBS/Emergent BioSolutions Quarterly
2023-08-09 10Q EBS/Emergent BioSolutions Quarterly
2023-05-10 10Q EBS/Emergent BioSolutions Quarterly
2022-11-09 10Q EBS/Emergent BioSolutions Quarterly
2022-08-02 10Q EBS/Emergent BioSolutions Quarterly

Receive EBS News And Ratings

See the #1 stock for the next 7 days that we like better than EBS

EBS Financial Statistics

Sales & Book Value

Annual Sales: $1B
Cash Flow: $147.9M
Price / Cash Flow: 3.12
Annual Sales: $9.40
Price / Book: 0.86

Profitability

EPS (TTM): -4.10000
Net Income (TTM): $-208.8M
Gross Margin: $317.6M
Return on Equity: -35.94%
Return on Assets: -12.27%

Emergent BioSolutions Earnings Forecast

Key Emergent BioSolutions Financial Ratios

  • The Gross Profit Margin over the past 22 years for EBS is 31.05%.
  • The Selling, General & Administrative Expenses for EBS have been equal to 36.01% of Gross Profit Margin.
  • The Research & Development expenses have been 10.89% of Revenue.
  • The Interest Expense is -11.56% of Operating Income.
  • The Net Earning history of EBS is -74.34% of Total Revenues.
  • Per Share Earnings over the last 23 years have been positive in 12 years.

Emergent BioSolutions Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Biotechnology
Sector: Health Care
Current Symbol: EBS
CUSIP: 29089Q
Website: emergentbiosolutions.com

Debt

Debt-to-Equity Ratio: 1.3
Current Ratio: 2.88
Quick Ratio: 1.18

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 2.71

EBS Technical Analysis vs Fundamental Analysis

Sell
27
Emergent BioSolutions (EBS) is a Sell

Is Emergent BioSolutions a Buy or a Sell?